<DOC>
	<DOCNO>NCT00448539</DOCNO>
	<brief_summary>This study open-label extension Study E2080-A001-301 . All patient initiate study total daily dos receive end transition phase E2080-A001-301 ( 2400 3200 mg/day ) option , discretion Investigator , incrementally increase dos maximum 4800 mg/day . Safety variables seizure frequency monitor throughout study .</brief_summary>
	<brief_title>Open-Label Extension Study Rufinamide Given Adjunctive Therapy Patients With Refractory Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Completion Study E2080A001301 full compliance inclusion exclusion criterion study ( exclude criterion related seizure occurrence ) . 2 . Patient willing participate write consent sign patient legal guardian provide prior enter study undergo study procedure . In addition , patient unable provide write informed consent provide legal guardian , assent patient ( patient able ) must also obtain . 3 . Female patient nonchildbearing potential reason surgery , radiation , menopause ( least one year post onset ) ; female patient childbearing potential use least two approve method contraception ( intrauterine device [ IUD ] , implant , oral contraceptive , barrier method plus spermicide ) . Use lowdose estrogen oral contraceptive alone permit . Female patient childbearing potential must agree continue use two approve method contraception followup visit 30 day final dose study medication , whichever longer . EXCLUSION CRITERIA : 1 . Discontinuation Study E2080A001301 reason , termination study . 2 . Evidence noncompliance study drug ongoing AED dose Study E2080A001301 . 3 . Evidence clinically significant disease ( cardiac , respiratory , gastrointestinal , hepatic ( e.g. , ALT &gt; 3x ULN ) , hematologic , renal , psychiatric disease , etc . ) opinion Investigator could affect patient 's safety trial conduct . 4 . Progressive central nervous system ( CNS ) disease , include degenerative CNS disease progressive tumor . 5 . History alcohol abuse past 2 year . 6 . History suicide attempt within previous 10 year . 7 . Multiple drug allergy ( dematological , heatological organ toxicity ) one severe drug reaction . 8 . Concomitant use felbamate vigabatrin . 9 . Pregnancy . 10 . Clinically significant ECG abnormality . 11 . All patient diagnosis Congenital Short QT Syndrome . Patients family history Congenital Short QT Syndrome may exclude basis Investigator 's clinical judgement . 12 . Presence major active psychiatric disorder . Patients allow take stable dose selective serotonin reuptake inhibitor ( SSRI ) mix serotonin norepinephrine uptake inhibitor antidepressant .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Refractory Partial Onset Seizures , epilepsy</keyword>
</DOC>